Bradley Canino
Stock Analyst at Stifel
(0.92)
# 3,490
Out of 4,778 analysts
94
Total ratings
25%
Success rate
-17.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $1.69 | +787.57% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $0.72 | +109.53% | 8 | Mar 7, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $2.97 | +675.72% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $8.13 | +527.31% | 6 | Feb 12, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $70 → $115 | $30.92 | +271.93% | 2 | Dec 3, 2024 | |
| AFMD Affimed | Maintains: Hold | $5 → $4 | $0.88 | +353.51% | 5 | Nov 15, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $41 | $13.46 | +204.72% | 5 | Oct 14, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $7.13 | +166.67% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $10.51 | +299.62% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $20.26 | +97.43% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $75.03 | +79.94% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.75 | +196.30% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.15 | +773.36% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.87 | +436.19% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $46.96 | +110.82% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.17 | +545.16% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $8.30 | +381.93% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $130 | $93.08 | +39.66% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $31.80 | +72.96% | 4 | Feb 23, 2024 |
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $1.69
Upside: +787.57%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $0.72
Upside: +109.53%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $2.97
Upside: +675.72%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $8.13
Upside: +527.31%
Janux Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $70 → $115
Current: $30.92
Upside: +271.93%
Affimed
Nov 15, 2024
Maintains: Hold
Price Target: $5 → $4
Current: $0.88
Upside: +353.51%
Syndax Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $40 → $41
Current: $13.46
Upside: +204.72%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $7.13
Upside: +166.67%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $10.51
Upside: +299.62%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $20.26
Upside: +97.43%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $75.03
Upside: +79.94%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $6.75
Upside: +196.30%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.15
Upside: +773.36%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.87
Upside: +436.19%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $46.96
Upside: +110.82%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.17
Upside: +545.16%
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $8.30
Upside: +381.93%
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $93.08
Upside: +39.66%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $31.80
Upside: +72.96%